ArticleDiscover oncology2025
The effect of chloroquine on cervical cancer via the PI3K/AKT/MDM2 pathway.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- NCBP2 Regulates PGAM5-Mediated Mitophagy Via KIF23 Alternative Splicing To Promote Cervical Cancer ProgressionRun Title: NCBP2 Promotes Cervical Cancer Via Mitophagy.Applied biochemistry and biotechnology · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundCervical cancer (CC), the most prevalent malignant tumor in the female reproductive system, is characterized by its high incidence and mortality rates. Chloroquine(CQ), a 4-aminoquinoline drug originally used to prevent and treat malaria, has gained recognition as an adjuvant anti-cancer agent. However, whether chloroquine exhibits anti-CC activity and its underlying mechanisms remain unclear. This study aimed to elucidate chloroquine's anti-cancer effects, focusing on the PI3K/AKT/MDM2 pathway, by integrating network pharmacology and in vitro experiments.
methodsFirstly, CQ and its associated targets related to cervical cancer were identified using the PharmMapper, SwissTargetPrediction, DrugBank, GeneCards, and DisGeNET databases. A protein-protein interaction (PPI) network was constructed to screen for key targets. Furthermore, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were conducted to predict the underlying biological functions and mechanisms involved in the anti-colorectal cancer effects of CQ. Subsequently, CCK-8, colony formation, and wound-healing assays were performed to assess the impact of CQ treatment on the proliferation ability of HeLa cells. Cell apoptosis was analyzed using flow cytometry, and the expression of apoptosis-related proteins was determined through Western blotting. Finally, the effects of CQ on the PI3K/AKT/MDM2 signaling pathway were evaluated via Western blotting.
resultsA total of 7,846 potential treatment targets for CQ were identified, among which 126 were related to CC. Through PPI network analysis of 100 common targets, eight core targets were identified: TNF, MDM2, SLC6A4, GRIN1, CHRM1, EZH2, ACHE, and ADRB2. KEGG enrichment analysis revealed the PI3K/AKT signaling pathway as a central pathway of interest. Various concentrations of CQ (25, 50, and 75 µM) inhibited the viability of HeLa cells while showing no significant effect on H8 cells. Following treatment with CQ (25 µM and 75 µM), a reduction in proliferation and colony formation was observed in HeLa cells. Furthermore, CQ treatment led to an increase in the expression of apoptosis-related proteins (Bax, Bcl-2, cleaved-PARP) and a decrease in the expression of proteins associated with the PI3K/AKT/MDM2 signaling pathway (p-PI3K, p-AKT, and p-MDM2).
conclusionsThis study suggests that chloroquine may induce apoptosis by inhibiting the PI3K/AKT/MDM2 signalling pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.